Lupin launches Moxifloxacin Ophthalmic Solution

14 Feb 2020 Evaluate

Lupin has launched Moxifloxacin Ophthalmic Solution USP, 0.5%, for which United States Food and Drug Administration (USFDA) approval was received earlier. The product would be manufactured at Lupin's Pithampur Unit II facility, India.

Moxifloxacin Ophthalmic Solution USP, 0.5% is the AT2 rated generic equivalent of Moxeza of Novartis. It is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms. Moxifloxacin Ophthalmic Solution USP, 0.5% (RLD: Moxeza) had an annual sales of approximately $10 million in the U.S.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2097.65 5.70 (0.27%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×